Comparison of the performance of serological kits for Helicobacter pylori infection with European and Asian study populations  by Hoang, T.T.H. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01514.x
Comparison of the performance of serological kits for Helicobacter pylori
infection with European and Asian study populations
T. T. H. Hoang1,4, A.-S. Rehnberg2, T.-U. Wheeldon3, C. Bengtsson1, D. C. Phung4, R. Befrits2,
M. So¨rberg3 and M. Granstro¨m1
1Department of Clinical Microbiology, Microbiology and Tumour Biology Centre, 2Department of
Medicine, Gastroenterology Unit, 3Infectious Diseases Unit, Karolinska Institute, Karolinska University
Hospital Solna, Stockholm, Sweden and 4National Institute of Hygiene and Epidemiology, Hanoi,
Vietnam
ABSTRACT
Most commercial kits for the detection of Helicobacter pylori were developed and validated with Western
populations, and some have been found to perform less well with Asian populations. This study
compared the performances of three serological kits with Swedish and Vietnamese peptic ulcer patients
and asymptomatic individuals. The Pyloriset EIA-GIII and HM-CAP ELISA kits indicated that Asian
populations had lower antibody titres to H. pylori than European populations. Despite the difference, the
Pyloriset EIA-GIII kit performed well with Vietnamese peptic ulcer patients and population controls.
The HM-CAP ELISA kit had a signiﬁcantly lower performance with Asian populations that could not be
improved by adjustments to the cut-off level. The Helicoblot 2.1 immunoblot kit performed equally well
with Vietnamese and Swedish populations, although the response rate to the 35-kDa band was
signiﬁcantly lower with Vietnamese individuals.
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INTRODUCTION
Helicobacter pylori infects half the population of the
world, causing chronic gastritis and peptic ulcer
disease (PUD), and has also been associated with
gastric cancer [1,2]. The infection can be con-
ﬁrmed by endoscopy, followed by culture of
H. pylori from biopsies. Non-invasive tests to
establish H. pylori infection, such as the urea
breath test, serological assays and detection of
antigen in faeces, are also used widely [3]. These
tests have advantages, especially for studies in
children and for epidemiological investigations.
ELISAs for detection of H. pylori are based on
antigens that are either whole-cell sonicates or
one or more puriﬁed components of the bacter-
ium. Both types of assay exist in the form of
in-house or commercially available formats.
It has been shown previously that the perform-
ance of in-house ELISAs can be improved for
serodiagnosis of H. pylori infection in Asian pop-
ulations by using local strains as antigens [4,5]. In
addition, asymptomatic H. pylori-infected popu-
lation controls have been shown to have lower
IgG levels than PUD patients, necessitating a
lower cut-off level for use in seroepidemiological
studies [4,6]. Although an in-house ELISA is less
expensive than a commercial kit, it presumes the
availability of equipment and the knowledge
necessary for large-scale culture of H. pylori for
antigen preparation and the removal of cross-
reactive antibodies [4]. Therefore, commercial
serological kits are often the only option for
serological diagnosis and seroepidemiological
studies in developing countries. However, sero-
logical kits for the diagnosis of H. pylori infection
were established and evaluated with Western
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populations. As a consequence, many kits have
been found to perform less well with Asian
populations [7–10].
The aim of the present study was to compare
the performance of two commercial ELISA kits
and an immunoblot kit with an in-house ELISA
with European (Swedish) and Asian (Vietnam-
ese) populations. The study also investigated
whether the assays could be improved by
adjusting the cut-off levels, thereby identifying
the optimal commercial test for use with Asian
populations.
MATERIALS AND METHODS
Study populations
The study populations comprised adults aged ‡ 18 years.
Ninety-one Swedish gastric ulcer (GU) patients and 270
Vietnamese PUD patients, all of whom were positive for
H. pylori by culture, had been identiﬁed previously in two
separate treatment trials [11,12]. The population controls
were 141 asymptomatic Swedish individuals, positive for
H. pylori by the 14C urea breath test, which has a sensitivity
of 93% and a speciﬁcity of 100% [13], and 429 Vietnamese
individuals who were diagnosed as H. pylori-positive or
-negative by the immunoblot kit, which was considered to
be the reference standard following evaluation in the other
three groups, as the urea breath test was not available in
Vietnam [4].
Diagnostic kits and in-house ELISA
The commercial kits used were Pyloriset EIA-GIII (Orion
Diagnostica, Espoo, Finland), HM-CAP (Enteric Products,
Westbury, NY, USA) and Helicoblot 2.1 (Genelabs, Singa-
pore). The Pyloriset EIA-GIII contains a partially puriﬁed
protein preparation of H. pylori collection strain NCTC
11637. A single cut-off level of 20 ELISA U ⁄mL is recom-
mended by the manufacturer for the Pyloriset EIA-GIII. In
order to compare the results of this assay with those of the
HM-CAP and the in-house ELISA, both of which normally
allow ±10% around the cut-off, single cut-off values were
also used for these assays. The HM-CAP kit, containing high
molecular mass cell-associated antigens, recommends that
ELISA values < 1.8 should be regarded as negative results,
those of 1.8–2.2 as intermediate, and values > 2.2 as
positives. The single cut-off value was set at 2.0. For the
in-house ELISA, local strains (i.e., from Swedish and
Vietnamese populations, respectively) were used in conjunc-
tion with the common cut-off level established previously at
OD405 0.22 [4]. The Helicoblot 2.1 immunoblot kit contains
H. pylori collection strain ATCC 49503, supplemented with a
recombinant antigen designated ‘current infection marker’
(CIM) [14]. The immunoblot kit was evaluated according
to the instructions of the manufacturer, with single bands
at 35 kDa, 37 kDa and 89 kDa (VacA), and with combina-
tions of these bands as the CIM, 19 kDa, 30 kDa (Urease A)
and 116 kDa (CagA) all being diagnostic for H. pylori
infection.
Statistical analysis
Sensitivity and speciﬁcity were calculated with exact binomial
95% CIs (STATA v. 8.0; Stata Corp., College Station, TX, USA).
Serological results were presented by reverse cumulative
distribution plot, as recommended previously for serological
data [15]. These curves allow results to be reviewed over the
entire range of absorbance values, with the shape of the curves
indicating the likelihood of intermediate results around a
given cut-off level. Receiver operating characteristic (ROC)
curve plots of test sensitivity and test speciﬁcity at different
cut-off levels were compared to evaluate and present test
performances [16].
Ethical approval
The study design and materials were approved by the Ethics
Committee of Karolinska University Hospital in Sweden (No.
98–260, 154 : 1 ⁄ 99, 02–031 and 96 ⁄ 063) and the Ethics Com-
mittee of the National Institute of Hygiene and Epidemiology
in Vietnam.
RESULTS
All four assays showed high sensitivity levels of
96.7–100% with the Swedish populations and the
Vietnamese PUD patients, with the exception of
the HM-CAP kit, which was signiﬁcantly
(p <0.001) less sensitive than the other assays
(Table 1). With the Vietnamese population con-
trols, and the immunoblot as reference, the in-
house ELISA and the Pyloriset EIA-GIII kit
performed well, while the HM-CAP kit had a
lower sensitivity and speciﬁcity (Table 2). A cause
for the discrepant results is illustrated by
Fig. 1(A–C), which shows lower antibody titres
in the Vietnamese populations compared with the
Swedish populations. The lower IgG titres were
particularly noticeable in the Vietnamese popula-
tion controls.
In order to improve the performance of the
assays, ROC curves were constructed for the
Pyloriset EIA-GIII and HM-CAP kits (Fig. 2), as
constructed previously for the in-house ELISA [4].
The data indicated that the performance of the
Pyloriset EIA-GIII kit could be improved further
with the two Vietnamese populations by slightly
lowering the cut-off level to 19, while the per-
formance of the HM-CAP kit at the indicated
optimal cut-off level of 1.8 remained poor.
The performance of the immunoblot (Helico-
blot 2.1 kit) was also investigated with the two
populations (Fig. 1D). A major difference was
noted only for the antibody response to the 35-
kDa antigen, where a response was signiﬁcantly
(p <0.001) less frequent with the Vietnamese
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populations in comparison with the Swedish
populations. As this band alone is diagnostic for
H. pylori infection, a lower rate of response to this
antigen among Asians could decrease the sensi-
tivity of the immunoblot for Asians compared
with Europeans. However, the performance of the
immunoblot was excellent with both populations,
as an isolated response to this band was not noted
with any of the study populations.
DISCUSSION
The present study demonstrated a variable per-
formance of the serological kits used for serodi-
agnosis of H. pylori infection among products,
among populations (i.e., European vs. Asian),
within these populations, and among subjects
with asymptomatic infection and those with PUD.
In the Vietnamese populations, asymptomatic
individuals had lower antibody titres than PUD
patients by all the ELISA-based assays included in
the study. The same observation has been repor-
ted previously for the in-house ELISA [4]. This
difference was not seen with the asymptomatic
Swedish patients and the Swedish GU patients.
The most plausible explanation would seem to be
that GU patients have less inﬂammatory re-
sponse, and possibly more atrophy, than PUD
patients, of whom the majority had duodenal
ulcer (DU), some had DU and GU, and only a few
had GU.
In order to test this hypothesis, the in-house
ELISA results obtained with 158 H. pylori culture-
positive Swedish DU patients from another trial
[17] were compared with the two Swedish study
populations in the present study (data not
shown). The DU patients had signiﬁcantly higher
antibody concentrations than the other two pop-
ulations, with the magnitude of the difference
being even more pronounced than with the
Vietnamese study populations. The important
difference in the height of the antibody response
between DU patients and asymptomatic individ-
uals (and GU patients) has relevance for the
choice of cut-off level. If H. pylori culture-positive
DU patients are used as the reference, the cut-off
level might be set too high for screening purposes
and for seroepidemiological studies. The differ-
ence might also explain, in part, some of the
divergent results obtained in evaluations of com-
mercial kits with Asian populations, in which the
kits perform well with DU patients, but less so
with other H. pylori-infected groups.
The performance of the HM-CAP kit was
equally good with symptomatic and asympto-
matic Europeans, but was inferior with the Asian
populations when compared with the other
methods investigated (i.e., in-house ELISA with
strains from the study population, the Pyloriset
Table 1. Sensitivity of in-house ELI-
SA, Pyloriset EIA-GIII, HM-CAP
and Helicoblot 2.1 kits for serodiag-
nosis of Helicobacter pylori infection
Population
Sensitivity of assay (%)
In-house ELISA
95% CI
(n ⁄ n total)
Pyloriset EIA-GIII
95% CI
n ⁄ n total)
HM-CAP
95% CI
(n ⁄ n total)
Helicoblot 2.1
95% CI
(n ⁄ n total)
Culture-positive 97.8 96.7 97.8 98.9
Swedish 92.3–99.7 90.7–99.3 92.3–99.7 94.0–100
GU patients (89 ⁄ 91) (88 ⁄ 91) (89 ⁄ 91) (90 ⁄ 91)
UBT-positive 99.3 99.3 100 100
Swedish 96.1–100 96.1–100 97.4–100 97.4–100
asymptomatic patients (140 ⁄ 141) (140 ⁄ 141) (141 ⁄ 141) (141 ⁄ 141)
Culture-positive 99.6 98.5 91.5 99.6
Vietnamese 98.0–100 96.3–99.6 87.5–94.5 98.0–100
PUD patients (269 ⁄ 270) (266 ⁄ 270) (247 ⁄ 270) (269 ⁄ 270)
GU, gastric ulcer; UBT, urea breath test; PUD, peptic ulcer disease.
Table 2. Sensitivity and speciﬁcity of the ELISA assays
with Vietnamese population controls, with the Helicoblot
2.1 kit as the reference standard method
Sensitivity Western blot (+) (n = 375)
% positives
in assays 95% CI
ELISA (in-house) 93.9 90.9–96.1
Pyloriset EIA-GIII 84.8 80.8–88.3
HM-CAP 77.6 73.0–81.7
Speciﬁcity Western blot (–) (n = 54)
% negatives
in assays 95% CI
ELISA (in-house) 90.7 79.7–96.9
Pyloriset EIA-GIII 94.4 84.6–98.8
HM-CAP 88.9 77.4–95.8
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EIA-GIII and the Helicoblot 2.1 immunoblot kits).
The performance of the HM-CAP kits with Asian
populations could not be improved signiﬁcantly
by adjustment of the cut-off level. The results thus
conﬁrm the observations of Marchildon et al. [10]
of major differences among Asian and European
strains with respect to the high molecular size
cell-associated proteins used as antigens in this
kit.
The Pyloriset EIA-GIII kit performed well with
all four study groups (i.e., Swedish asymptomatic
H. pylori-infected individuals, Swedish GU pa-
tients, Vietnamese immunoblot-positive asymp-
tomatic population controls and Vietnamese PUD
patients). The performance of an earlier version of
this kit was reported to be less than optimal with
a Chinese population [7]. However, the current
version of the kit showed the same high degree of
sensitivity with Thai dyspeptic patients [18] as
found in the present study. In the Thai study, all
the kits tested had a low speciﬁcity, but these
determinations suffered from the difﬁculties
entailed when trying to identify true-negatives,
especially in an Asian setting. When using the
immunoblot as a reference standard in the present
study, the speciﬁcity of the Pyloriset EIA-GIII
kit was high with the Vietnamese population
controls.
The Helicoblot 2.1 immunoblot kit has been
evaluated previously for sensitivity and speciﬁc-
ity with Japanese and American populations with
respect to the putative virulence factors CagA
(89 kDa) and VacA (119 kDa), and has yielded
good results [14]. The present evaluation of all the
bands showed that the kit performed equally well
with respect to sensitivity with European and
Asian populations. The only signiﬁcant difference
was the lower response rate to the 35-kDa protein
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Fig. 1. A–C, Reverse cumulative graphs of antibody concentrations in the ELISA assays. The dotted lines represent cut-off
levels in the respective assays. D, Proportion of responders to the diagnostic bands in the Helicoblot 2.1 kit (Vn,
Vietnamese; Sw, Swedish; PUD, peptic ulcer disease; GU, gastric ulcer).
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with the Vietnamese study populations, but this
did not impact negatively on the sensitivity of the
kit.
In conclusion, this study demonstrated that
Vietnamese study populations have lower anti-
body responses to the H. pylori antigens contained
in commercial kits than do Swedish populations.
Despite this difference, the commercial Pyloriset
EIA-GIII kit performed well with Asian popula-
tions, and the performance of the kit could be
improved further by a slight lowering of the cut-
off level. In contrast, the HM-CAP kit showed a
poor performance that could not be improved
signiﬁcantly by adjusting the cut-off level. The
Helicoblot 2.1 immunoblot kit performed equally
well with all the populations tested, despite a
difference in the response rate to one band
between Swedish and Vietnamese individuals.
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